Verve Therapeutics Inc Share Price

NASDAQ: VERV

$11.14

+0.04

(+0.36%)

as on July 25, 2025 at 1:29 am IST

$₹

The stock has been delisted from the stock exchange on 24 Jul 2025

Verve Therapeutics Inc Stock Performance

as on July 25, 2025 at 1:29 am IST

Day's Low
Day's High
$11.13
Day's Price Range
$11.13
$11.14
0.09%
Downside
-0.09%
Upside
52 Week's Low
52 Week's High
$2.86
52-Week Price Range
$11.41
$11.14
74.28%
Downside
2.38%
Upside

Verve Therapeutics Inc share price movements today

Previous Close: $11.10
Open: $11.13
Volume: 15.5K
Day's Low - High: $11.13 - $11.13
52 Week Low - High: $2.86 - $11.41

Verve Therapeutics Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Verve Therapeutics Inc Stock Fundamentals & Key Indicators

Check Verve Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

Verve Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Verve Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Verve Therapeutics Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Verve Therapeutics Inc Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Verve Therapeutics Inc. Average target price of $15.11

Verve Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Verve Therapeutics Inc.

What analysts predicted

26.27%UPSIDE

Target Price

$15.11

Current Price

$11.14

Analyzed by

17 Analysts

Target

$15.11

Verve Therapeutics Inc target price $15.11, a slight upside of 26.27% compared to current price of $11.14. According to 17 analysts rating.

Verve Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	1	1	2	3	5	5	6	6	13	32
Gross Profit	-1	-1	0	0	5	5	6	6	13	32
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-41	-45	-53	-45	-48	-48	-49	-50	-50	-31
Net Profit Margin	-4059.78%	-3254.34%	-2579.22%	-1468.01%	-939.97%	-855.77%	-744.25%	-730.27%	-382.53%	-94.11%

Verve Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	1	11	32
Gross Profit	0	-1	-3	1	11	32
Operating Income	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-
Net Income	-19	-45	-118	-157	-200	-198
Net Profit Margin	0.00%	0.00%	0.00%	-8108.55%	-1701.55%	-614.59%

Global Institutional Holdings in Verve Therapeutics Inc

Funds	Holdings
Alphabet Inc	13.83%
BlackRock Inc	8.82%
Bvf Inc	7.73%
Casdin Capital, LLC	4.47%
Vanguard Group Inc	4.43%

See all

About Verve Therapeutics Inc

Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.

Organisation	Verve Therapeutics Inc
E-voting on shares	Click here to vote

FAQs

What is Verve Therapeutics Inc share price today?

Verve Therapeutics Inc share price today is $11.14 as on July 25, 2025 at 1:29 am IST at the close of the market. Verve Therapeutics Inc share today touched a day high of $11.13 and a low of $11.13.

What is the 52 week high and 52 week low for Verve Therapeutics Inc share?

Verve Therapeutics Inc share touched a 52 week high of $11.41 on June 17, 2025 and a 52 week low of $2.86 on April 9, 2025. Verve Therapeutics Inc stock price today i.e. July 25, 2025 at 1:29 am IST is closed at $11.14,which is 2.32% down from its 52 week high and 288.87% up from its 52 week low.

How to invest in Verve Therapeutics Inc Stock (VERV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Verve Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Verve Therapeutics Inc Shares that will get you 0.1346 shares as per Verve Therapeutics Inc share price of $11.14 per share as on July 25, 2025 at 1:29 am IST.

What is the minimum amount required to buy Verve Therapeutics Inc Stock (VERV) from India?

Indian investors can start investing in Verve Therapeutics Inc (VERV) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 6:18 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Verve Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 6:18 am IST). Based on Verve Therapeutics Inc share’s latest price of $11.14 as on July 25, 2025 at 1:29 am IST, you will get 0.8977 shares of Verve Therapeutics Inc. Learn more about fractional shares .